Holocene Advisors, LP Arvinas, Inc. Transaction History

Holocene Advisors, LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$14.19 - $42.33 $10.6 Million - $31.5 Million	744,465 New	744,465 $30.6 Million
Q3 2020 Nov 16, 2020	SELL	$22.99 - $36.34 $8.15 Million - $12.9 Million	-354,622 Closed	0 $0
Q2 2020 Aug 14, 2020	SELL	$29.88 - $56.74 $1.98 Million - $3.76 Million	-66,327 Reduced 15.76%	354,622 $11.9 Million
Q1 2020 May 15, 2020	BUY	$33.0 - $54.5 $11.4 Million - $18.8 Million	344,454 Added 450.3%	420,949 $17 Million
Q4 2019 Feb 14, 2020	BUY	$15.39 - $44.38 $1.18 Million - $3.39 Million	76,495 New	76,495 $3.14 Million

229

68.4M

226K

285K

Ticker ARVN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,205,300
Market Cap $997M
Description
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...

Get notified when there are updates to the investment portfolio of Holocene Advisors, LP, based on Form 13F filings with the SEC.

Stay updated on Holocene Advisors, LP with notifications on news.